Skip to content

iktos vs Optibrium

iktos logo

iktos

Artificial intelligence for new drug design

62 employees · est. 2016 · Paris, France

VS
Optibrium logo

Optibrium

elegant software that guides successful drug discovery

44 employees · est. 2009 · Cambridge, United Kingdom

Optibrium is the older company (2016 vs 2009); iktos is the larger of the two.

Side-by-Side Comparison

iktos Optibrium
Founded
2016 2009 older
Headquarters
Paris, France Cambridge, United Kingdom
Employees
62 larger 44
Industry
AI, Biotechnology, Health Care Biotechnology, Pharmaceutical
Funding Stage
Series A Growth
Total Funding
$18.90M $1.00M
Funding Rounds
7 4
Services
Generative AI Platform (Makya), AI-Driven Retrosynthesis (Spaya), Automated Drug Development Pipeline, Autonomous Lab Robotics AI-guided drug discovery, Real-time collaboration for molecular design, 3D ligand-based and structure-based design, Metabolism insights for DMPK scientists, Chemical discovery pipeline optimization
Target Customers
Pharmaceutical Companies, Biotech Firms, Academic Institutions, Medicinal and Computational Chemists, Drug Discovery Teams Pharmaceutical companies, Biotechnology firms, Medicinal chemists, DMPK scientists, R&D teams in chemical and drug discovery
Taxonomy
Drug DesignMedicinal ChemistryGenerative AIChemoinformaticsRobotics AutomationSaaS Software +8 Drug Discovery SoftwareSmall Molecule DesignOptimisationStarDropPredictive ModellingAugmented Chemistry +7
Website
iktos.ai optibrium.com
iktos logo

About iktos

Iktos, founded in 2016 and headquartered in France, stands out as a leader in the convergence of AI and biotechnology for drug discovery. Its slogan, "Artificial intelligence for new drug design," encapsulates its mission to leverage cutting-edge technologies for medicinal chemistry. The company's...

Optibrium logo

About Optibrium

Optibrium, founded in 2009 and headquartered in Cambridge, UK, offers software solutions that enhance the efficiency and productivity of small molecule drug discovery. With its flagship product, StarDrop™, Optibrium provides an integrated software suite delivering predictive modeling and decision-ma...

Also comparing in this category

Comparing more than these two?

Get iktos, Optibrium and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does iktos compare?

A PDF of iktos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

iktos was founded in 2016, based in Paris, France, with 62 employees. Iktos, founded in 2016 and headquartered in France, stands out as a leader in the convergence of AI and biotechnology for drug discovery. Its slogan, "Artificial intelligence for new drug design," enc. Optibrium was founded in 2009, based in Cambridge, United Kingdom, with 44 employees. Optibrium, founded in 2009 and headquartered in Cambridge, UK, offers software solutions that enhance the efficiency and productivity of small molecule drug discovery. With its flagship product, StarD.
iktos has raised $18.90M and Optibrium $1.00M. Latest stage: iktos Series A, Optibrium Growth.
Both work in Biotechnology and Pharmaceutical and list medicinal chemistry among their focus areas.

Compare iktos with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at iktos on 20 Sep 2026, and Optibrium on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout